Renova Therapeutics is working to create a portfolio of definitive one-time gene therapy treatments as well as peptide infusion therapies to restore health to people suffering from cardiovascular and metabolic diseases. The first indications the company is pursuing are gene therapies for congestive heart failure (CHF) and type 2 diabetes, two of the most common and devastating chronic diseases in the world. Along with single-dose gene therapies, Renova Therapeutics is also developing a peptide infusion treatment for the periods in which CHF patients are hospitalized for Acute Decompensated Heart Failure.